

Docket No. 434-226

Patent

AMENDED VERSION WITHOUT MARKINGS

B<sup>1</sup> 20. (Amended) A method of inducing rapid onset and long lasting sedation and analgesia in an animal, comprising administering to the animal a pharmaceutically effective amount of a composition consisting essentially of a guanidine derivative.

B<sup>2</sup> 36. (New) A method of inducing rapid onset and long lasting sedation and analgesia in a standing equine animal, comprising administering to the animal a pharmaceutically effective amount of a composition comprised of a guanidine derivative.

B<sup>2</sup> 37. (New) The method of claim 36, wherein the guanidine derivative is selected from the group consisting of guanabenz, guanabenz acetate, guanoxabenz, clonidine, guanacline, guanadrel, guanabenzidine, guanethidine, guanfacine and guanochlor, guanoxan and clonidine.

B<sup>2</sup> 38. (New) The method of claim 36, wherein the guanidine derivative is guanabenz acetate or pharmaceutically acceptable derivatives thereof.

39. (New) The method of claim 36, wherein the administration is oral.
40. (New) The method of claim 36, wherein the administration is intravenous.
41. (New) The method of claim 36, wherein the administration is intramuscular.
42. (New) The method of claim 36, further comprising the step of selectively reversing or controlling the level of analgesia and sedation in the animal comprising administering a pharmaceutically effective amount of  $\alpha$  adrenergic antagonist to the animal.
43. (New) The method of claim 42 wherein the  $\alpha$  adrenergic antagonist is selected from the group consisting of yohimbine, rauwolscine, idazoxan and atepamezole.
44. (New) The method of claim 36, wherein the pharmaceutically effective amount of the guanidine derivative is between about 0.05 mg/kg and about 0.50 mg/kg.
45. (New) The method of claim 36, wherein the pharmaceutically effective amount of the guanidine derivative is about 0.25 mg/kg.

B<sup>2</sup> ent

46. (New) The method of claim 36, wherein the guanidine derivative is guanabenz acetate or a pharmaceutically acceptable derivative thereof and the pharmaceutically effective amount is between about 0.05 mg/kg and about 0.50 mg/kg.

B<sup>2</sup> cont

47. (New) The method of claim 36, wherein the guanidine derivative is guanabenz acetate or a pharmaceutically acceptable derivative thereof and the pharmaceutically effective amount is about 0.25 mg/kg.

48. (New) The method of claim 36, wherein the guanidine derivative is an  $\alpha$ -adrenergic agonist.
-